The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study
- 23 November 2022
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 32 (1) , 94-100
Abstract
Objective: To investigate the efficacy and safety of telitacicept treatment in a Chinese SLE cohort, with real-life settings. Methods: All patients with SLE who were receiving telitacicept treatment at least 4 weeks were included, and were followed up. Patients received subcutaneous injection of telitacicept weekly based on the standard treatment. SLE responder index-4 (SRI-4) was assessed before the first administration and at least 4 weeks after the first administration. Disease flares during the follow-up period were defined as an increase in disease activity and the number or dose of immunosuppressive drugs. Results: After 4–45 weeks’ administration of telitacicept, 80% ( n = 16) reached SRI-4 response. The prednisolone dosage declined from a mean of 30.25 mg/d (95% CI 21.99–38.51) before treatment to 13.25 mg/d (95% CI 9.92–16.58) after treatment. The proportion of patients without receiving an immunosuppressive drug increased from 15% to 43% at the endpoint. 19 cases showed various reduction of IgM after treatment ( p < 0.05) and C3 and C4 showed either stable or an upward trend. The 24 h urinary protein median value of the 14 cases (baseline 24 h urinary protein >0.5 g/d) showed significant reduction, and 7 of them turned negative. Adverse events were mild to moderate and controllable. Conclusion: Telitacicept is a potential treatment option for patients with SLE, especially in lupus nephritis, with significantly increased SRI-4 response rate and reduced the glucocorticoid and immunosuppressive drugs.Keywords
Funding Information
- Scientific and Technological Planning Project of Guangzhou City (202201020113)
- Guangdong Basic and Applied Basic Research Foundation (2021A1515011007)
- National Natural Science Foundation of China (81801614)
This publication has 20 references indexed in Scilit:
- Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activityAnnals of the Rheumatic Diseases, 2019
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyThe Lancet, 2018
- Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directionsCurrent Opinion in Rheumatology, 2018
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet, 2018
- Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic reviewSeminars in Arthritis and Rheumatism, 2017
- Lupus nephritis and B-cell targeting therapyExpert Review of Clinical Immunology, 2017
- Pathways leading to an immunological disease: systemic lupus erythematosusRheumatology, 2017
- Glucocorticoids and irreversible damage in patients with systemic lupus erythematosusRheumatology, 2014
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosusRheumatology, 2005